Akero Therapeutics Inc. (AKRO)
21.85
-0.78 (-3.45%)
At close: Jan 14, 2025, 3:59 PM
22.38
2.43%
Pre-market Jan 15, 2025, 06:26 AM EST
undefined% (undefined)
| Bid | 21.47 |
| Market Cap | 1.53B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -3.78 |
| PE Ratio (ttm) | -5.78 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 22.87 |
| Volume | 1,041,577 |
| Avg. Volume (20D) | 641,716 |
| Open | 22.81 |
| Previous Close | 22.63 |
| Day's Range | 21.34 - 23.20 |
| 52-Week Range | 15.32 - 37.00 |
| Beta | undefined |
About AKRO
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a ...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 20, 2019
Employees 60
Stock Exchange NASDAQ
Ticker Symbol AKRO
Website https://www.akerotx.com
Analyst Forecast
According to 8 analyst ratings, the average rating for AKRO stock is "Buy." The 12-month stock price forecast is $46, which is an increase of 110.53% from the latest price.
Buy 87.50%
Hold 12.50%
Sell 0.00%
10 months ago ·
Source
+11.72%
Akero Therapeutics shares are trading higher after...
Unlock content with
Pro Subscription
